“In taking Amgen but not Bristol, the court may have wanted to wade into this complex area one toe at a time,” one expert said.
News
STAT+: Pharmalittle: Appeals court rules Purdue can shield Sacklers from lawsuits; chemo shortage blamed on drugmakers’ lack of investment
A U.S. appeals court ruled that Purdue Pharma can shield its owners from lawsuits over the company’s role in the opioid crisis as part of a bankruptcy settlement. […]
News
STAT+: Pharmalittle: FDA increasingly pausing trials of experimental meds; FDA commish isn’t surprised by congressional report on Alzheimer’s drug
The FDA is pressing pause on testing of experimental medicines more often, a side effect of the drug industry’s move into promising but less-proven technologies. […]
News
STAT+: Pharmalittle: Where is PhRMA in the abortion pill debate? Most late-stage MS drug trials were never published
Stanford’s president took responsibility for the decision not to correct or retract a paper at the heart of a research misconduct investigation. […]
